Diagnostic Center | May 28, 2024
Ascentage releases results from multiple clinical studies of its lead drug candidates
These abstracts report on the company's three lead drug candidates, including olverembatinib
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Subscribe To Our Newsletter & Stay Updated
